Case StudyAsparaginase-associated concurrence of hyperlipidemia, hyperglobulinemia, and thrombocytosis was successfully treated by centrifuge/membrane hybrid double-filtration plasmapheresis
Section snippets
Case report
A 50-year-old male was admitted in August 2014 to receive a planned third chemotherapy. He was diagnosed as NK/T-cell lymphoblastic lymphoma 2 months previously and had received chemotherapy (DDGP protocol: cisplatin + dexamethasone + gemcitabine + pegaspargase) for 2 times. After admission, the planned third chemotherapy was postponed as laboratory tests revealed a severe hyperlipidemia (serum triglycerides = 37.79 mmol/L, total cholesterol = 19.76 mmol/L), elevation of platelet count (380 × 10
Discussion
The underlying mechanism for hyperlipidemia in asparaginase treatment seems to be an increase of endogenous synthesis of very low-density lipoprotein, decreased lipoprotein lipase activity, and reduction of apoE lipoprotein receptor synthesis.4, 5, 6, 7 Corticosteroids may aggravate it by augmenting the synthesis of triglycerides.4 Elevation of triglycerides-rich chylomicrons in blood is the main manifestation, and blood low-density lipoprotein level is usually normal.8 For this case, another
Acknowledgment
We wish to thank the nurses involved in this study.
References (11)
- et al.
Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia
Blood
(1997) - et al.
Toxicity of E. coli L-asparaginase in man
Cancer
(1970) - et al.
L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia
Rinsho Ketsueki
(1991) Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase
Cancer
(1994)- et al.
The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia
Eur J Pediatr
(1988)
Cited by (2)
No funding was received for this research.